The company pled guilty to one misdemeanor charge and paid a fine of $15 million. As a result, the department of justice dismissed 13 felony charges against the company. The company was charged with marketing unapproved products for human bone growth, according to Bloomberg Businessweek news report.
Stryker’s misbrand may have led surgeons to combine the company’s OP-1 and OP-1 Putty with bone filler Calstrux, which could have adverse events.
Related Articles on Orthopedic Devices:
Zyga Technology Names Jim Bullock President & CEO
Zimmer Acquires Synvasive Technology
VG Innovations Releases Spine Device for Low Back Pain
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
